HZB coordinates European collaboration to develop active agents against Corona

The MX team at BESSY II specialises in analysing protein structures. This can also accelerate the development of drugs against COVID-19.

The MX team at BESSY II specialises in analysing protein structures. This can also accelerate the development of drugs against COVID-19. © HZB

X-ray structure analysis at BESSY II enables the systematic testing of many thousands of molecules that could inhibit the reproduction and virulence of SARS-CoV2 viruses. Now, a team at HZB with partners from Austria and the Czech Republic has set up the NECESSITY project to investigate more than 8000 compounds in a high-throughput procedure and develop active agents against COVID-19.

The COVID-19 pandemic is far from over. Despite the rapid development of vaccines, it is not possible, for various reasons, to give everyone lasting protection through vaccination quickly enough. But so far, there are hardly any effective drugs for patients severely affected by COVID-19. Therapy is mainly limited to the administration of steroid drugs to control the immune reaction and artificial respiration.

Researchers around HZB-scientist Dr. Christian Feiler have initiated a three-party European research study termed NECESSITY, led by project partner Prof. Dr. Klaus Scheffzek (Med. University Innsbruck, Austria). Their goal is to investigate detailed interactions between Sars-CoV-2 proteins and chemical compounds developed and provided by Dr. Vladimír Kryštof (Palacký University Olomouc, the Czech Republic), using structural and biochemical approaches. X-ray structure analysis at BESSY II enables the systematic testing of many thousands of molecules that could inhibit the reproduction and virulence of SARS-CoV2 viruses. This research is funded by the Austrian Science Fund (FWF), the German Research Foundation (DFG), and the Czech Science Foundation (GACR).

At the light source BESSY II, which is operated by HZB, the structural analysis of macromolecules provides a fantastic tool to accelerate the development of effective substances against the SARS-CoV2 virus. The three-dimensional structure of the so-called viral main protease was determined at BESSY II for the first time at the beginning of 2020. This enzyme is indispensable for virus replication. However, it is not sufficient to investigate this one target, which is why several viral target proteins are being addressed in the NECESSITY project. The consortium will explore more than 8000 compounds at the MX-beamlines of BESSY II in a high-throughput procedure and identify substances from them that could dock to the main protease of SARS-CoV-2 or other target proteins. These drug-like candidates originate from a unique library generated and collected by Dr. Vladimír Kryštof, Palacký University Olomouc. All compounds are either already approved for the treatment of other diseases or are in various clinical phases. If hits were to come out of this, it would be possible to develop drugs against COVID-19 remarkably quickly. Prof. Dr. Klaus Scheffzek and his team at the Medical University in Innsbruck can investigate the hit compounds in detail using biophysical methods and initiate the first virological studies. Prof. Dr. Christian Drosten, Director of the Institute of Virology at Charité Berlin, and other experts are also on board as advisors and partners.

"In the NECESSITY project, we bring together expertise from different fields," says Feiler. "Together, we have planned a very efficient interdisciplinary workflow to identify antiviral substances that can be used as effective drugs against COVID-19 and beyond as quickly as possible."  

The project is funded by the German Research Foundation and the corresponding funding organizations in Austria and the Czech Republic for 36 months with almost 800,000 Euros.

 

 

 

arö

  • Copy link

You might also be interested in

  • Leading Sasol scientist appointed as Industrial Research Fellow at HZB
    News
    11.02.2025
    Leading Sasol scientist appointed as Industrial Research Fellow at HZB
    Within the CARE-O-SENE project, HZB is cooperating with the South African company Sasol on innovative catalysts for sustainable aviation fuels (SAF). Now, the collaboration is intensifying: Dr. Denzil Moodley, a leading scientist in the field of Fischer-Tropsch at Sasol Research and Technology, is being appointed as Industrial Research Fellow at HZB. Moodley will contribute his expertise at HZB with the aim of accelerating the innovation cycle for sustainable fuel technologies.
  • Nanoislands on silicon with switchable topological textures
    Science Highlight
    20.01.2025
    Nanoislands on silicon with switchable topological textures
    Nanostructures with specific electromagnetic patterns promise applications in nanoelectronics and future information technologies. However, it is very challenging to control those patterns. Now, a team at HZB examined a specific class of nanoislands on silicon with interesting chiral, swirling polar textures, which can be stabilised and even reversibly switched by an external electric field.
  • Lithium-sulphur pouch cells investigated at BESSY II
    Science Highlight
    08.01.2025
    Lithium-sulphur pouch cells investigated at BESSY II
    A team from HZB and the Fraunhofer Institute for Material and Beam Technology (IWS) in Dresden has gained new insights into lithium-sulphur pouch cells at the BAMline of BESSY II. Supplemented by analyses in the HZB imaging laboratory and further measurements, a new picture emerges of processes that limit the performance and lifespan of this industrially relevant battery type. The study has been published in the prestigious journal Advanced Energy Materials.